NCT01973595

Brief Summary

The purpose of this study is to determine whether incorporating almonds into the diets of families with young children will induce beneficial changes in gastrointestinal function, the fecal microbiota profile, and immune and inflammatory processes of the adults and children resulting in improved quality of life. The investigators anticipate finding an increase in beneficial bacteria, improved intestinal function, and decreased inflammation during the almond intervention.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P50-P75 for not_applicable healthy

Timeline
Completed

Started Dec 2013

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 15, 2013

Completed
16 days until next milestone

First Posted

Study publicly available on registry

October 31, 2013

Completed
1 month until next milestone

Study Start

First participant enrolled

December 1, 2013

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2014

Completed
2 years until next milestone

Results Posted

Study results publicly available

April 25, 2016

Completed
Last Updated

May 26, 2016

Status Verified

April 1, 2016

Enrollment Period

5 months

First QC Date

October 15, 2013

Results QC Date

November 12, 2015

Last Update Submit

April 26, 2016

Conditions

Keywords

almondsinflammationimmunitygut microbiotastressdiet quality

Outcome Measures

Primary Outcomes (1)

  • Gut Microbiota Community Composition

    The mean of the change between baseline and final time points in stool lactic acid bacteria counts \[log(CFU)\] was compared for each study arm.

    Baseline #1 (Week 1) to Final #1 (Week 4) of each intervention

Secondary Outcomes (3)

  • Inflammatory Status

    Change between Baseline to Week 4

  • Gastrointestinal Function

    Pre-baseline (Week 0) and Week 3 of each intervention

  • Diet Quality

    Three week almond intervention vs. three week no almond intervention

Study Arms (2)

Almonds then no almonds

EXPERIMENTAL

Adults will consume 1.5 ounces of almonds or almond paste per day and children will consume 0.5 ounces of almonds or almond paste per day for 3 weeks.

Dietary Supplement: Almonds, Then no almonds

No almonds then almonds

OTHER

No almonds will be consumed by participants for 3 weeks.

Other: No Almonds, Then almonds

Interventions

Almonds, Then no almondsDIETARY_SUPPLEMENT

Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.

Almonds then no almonds

No almonds will be consumed by participants for 3 weeks.

No almonds then almonds

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • To participate in the study, adult participants must:
  • Be 18 to 40 years old.
  • Have a 3 to 6 year old child that you are willing to enroll in the study.
  • Live with your child for on average at least 6 days of the week.
  • Be willing and able to complete the Informed Consent Form in English.
  • Not be currently pregnant or planning to become pregnant in the next 5 months.
  • Be willing to consume 1.5 ounces of almonds (\~43 nuts) each day for three weeks.
  • Be willing to feed your child 0.5 ounces of almond paste (\~2 tablespoons) per day for three weeks.
  • Be willing monitor your child's daily intake over the course of the study.
  • Be willing to provide 4 blood samples, 4 stool samples, and 4 saliva samples over the course of the study.
  • Be willing to assist your child in providing 4 stool samples and 4 saliva samples over the course of the study.
  • Be willing and able to complete daily and weekly questionnaires for you and your child regarding general wellness, bowel function, gastrointestinal symptoms, stress and anxiety, and dietary intake.
  • Must be available for 14 consecutive weeks to participate in the study.

You may not qualify if:

  • To participate in the study, adult and child participants:
  • Must not have any known nut or tree nut allergies.
  • Must discontinue any immune-enhancing dietary supplements (e.g., prebiotics and fiber supplements, probiotics, fish oil, vitamin E \>400% of the Recommended Dietary Allowance (RDA) or \>60 mg/day, and yogurts with live, active cultures).
  • Must not be currently taking any medications for constipation or diarrhea on a regular basis.
  • Must not be currently taking any large doses of anti-inflammatory drugs (i.e., aspirin in doses \>600 mg/d) on a regular basis.
  • Must not have received antibiotic therapy or a colonoscopy in the past two months.
  • Must not be currently being treated for or have any of the following physician-diagnosed diseases or conditions: HIV/AIDS; immune modulating diseases (autoimmune disease, hepatitis, cancer); kidney disease; pancreatitis; pulmonary disease; hepatic or biliary disease; or gastrointestinal diseases/conditions such as diverticulitis, ulcerative colitis, Crohn's disease, Celiac disease, short bowel disease, ileostomy, or colostomy, but not including gastroesophageal reflux disease; or have a central venous catheter.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Florida

Gainesville, Florida, 32611, United States

Location

Related Publications (1)

  • Burns AM, Zitt MA, Rowe CC, Langkamp-Henken B, Mai V, Nieves C Jr, Ukhanova M, Christman MC, Dahl WJ. Diet quality improves for parents and children when almonds are incorporated into their daily diet: a randomized, crossover study. Nutr Res. 2016 Jan;36(1):80-9. doi: 10.1016/j.nutres.2015.11.004. Epub 2015 Nov 10.

MeSH Terms

Conditions

Inflammation

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Dr. Bobbi Langkamp- Henken
Organization
University of Florida

Study Officials

  • Bobbi Langkamp-Henken, PhD, RD

    University of Florida

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 15, 2013

First Posted

October 31, 2013

Study Start

December 1, 2013

Primary Completion

May 1, 2014

Study Completion

May 1, 2014

Last Updated

May 26, 2016

Results First Posted

April 25, 2016

Record last verified: 2016-04

Locations